ERBB2 and breast carcinoma: For this subgroup, we observed, despite a small subgroup size, a large difference in NPVs between 1.5 T and 3.0 T. It might be, therefore, desirable to further investigate the influence of different field strengths on pCR prediction in specifically HR-positive/HER2-positive breast cancer, in DCE as well as in DWI.